These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29436674)

  • 1. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
    Oh YJ; Park SY; Seo YH
    Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel chalcone-based molecule, BDP inhibits MDA‑MB‑231 triple-negative breast cancer cell growth by suppressing Hsp90 function.
    Oh YJ; Seo YH
    Oncol Rep; 2017 Oct; 38(4):2343-2350. PubMed ID: 28849241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
    Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
    Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
    Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
    Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
    BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR.
    Hong YS; Jang WJ; Chun KS; Jeong CH
    Oncol Rep; 2014 Jun; 31(6):2619-24. PubMed ID: 24789511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
    Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
    J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells.
    Varghese E; Samuel SM; Varghese S; Cheema S; Mamtani R; Büsselberg D
    Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30563138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Cho TM; Kim JY; Kim YJ; Sung D; Oh E; Jang S; Farrand L; Hoang VH; Nguyen CT; Ann J; Lee J; Seo JH
    Cancer Lett; 2019 Apr; 447():141-153. PubMed ID: 30703411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
    Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
    Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
    Friedland JC; Smith DL; Sang J; Acquaviva J; He S; Zhang C; Proia DA
    Invest New Drugs; 2014 Feb; 32(1):14-24. PubMed ID: 23686707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
    Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
    Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
    Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
    Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.
    Byun HJ; Darvin P; Kang DY; Sp N; Joung YH; Park JH; Kim SJ; Yang YM
    Oncol Rep; 2017 Jun; 37(6):3270-3278. PubMed ID: 28440514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer.
    Kou X; Jiang X; Liu H; Wang X; Sun F; Han J; Fan J; Feng G; Lin Z; Jiang L; Yang Y
    Cancer Sci; 2018 Oct; 109(10):3272-3284. PubMed ID: 30039622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of Xi Huang pills on MDA‑MB‑231 cells in vitro and in vivo.
    Zheng W; Han S; Jiang S; He X; Li X; Ding H; Cao M; Li P
    Mol Med Rep; 2018 Aug; 18(2):2068-2078. PubMed ID: 29956784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.